B-Cell Maturation Antigen
"B-Cell Maturation Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily found on mature B-LYMPHOCYTES. It has specificity for B CELL ACTIVATING FACTOR and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Descriptor ID |
D053301
|
MeSH Number(s) |
D12.776.543.750.705.852.760.226
|
Concept/Terms |
B-Cell Maturation Antigen- B-Cell Maturation Antigen
- B Cell Maturation Antigen
- Maturation Antigen, B-Cell
- Receptors, Tumor Necrosis Factor, Member 17
- Tumor Necrosis Factor Receptor Superfamily, Member 17
- B Cell Maturation Protein A
- BCMA Protein
|
Below are MeSH descriptors whose meaning is more general than "B-Cell Maturation Antigen".
Below are MeSH descriptors whose meaning is more specific than "B-Cell Maturation Antigen".
This graph shows the total number of publications written about "B-Cell Maturation Antigen" by people in this website by year, and whether "B-Cell Maturation Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2018 | 1 | 0 | 1 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "B-Cell Maturation Antigen" by people in Profiles.
-
Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):383-406.
-
Razzo B, Garfall AL, Cohen AD. Options at the time of relapse after anti-BCMA therapy. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):450-458.
-
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. ?-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023 Jul; 24(7):811-822.
-
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018 08 01; 36(22):2267-2280.